These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
692 related items for PubMed ID: 7907097
1. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E. J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097 [Abstract] [Full Text] [Related]
2. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial. Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK. Psychopharmacol Bull; 1993 Dec; 29(2):303-8. PubMed ID: 7904761 [Abstract] [Full Text] [Related]
3. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects. Busto UE, Naranjo CA, Bremner KE, Peachey JE, Bologa M. J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058 [Abstract] [Full Text] [Related]
4. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group. Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921 [Abstract] [Full Text] [Related]
5. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo]. Lemoine P, Touchon J, Billardon M. Encephale; 1997 Dec; 23(4):290-9. PubMed ID: 9417395 [Abstract] [Full Text] [Related]
6. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE, Franznick DA, Hollander SB, Fava M. J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [Abstract] [Full Text] [Related]
7. Clinical assessment of the safety and efficacy of lorazepam, a new benzodiazepine derivative, in the treatment of anxiety. Pinosky DG. J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):24-9. PubMed ID: 30763 [Abstract] [Full Text] [Related]
8. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety]. Lôo H, Malka R, Hantouche E, Lancrenon S, Guelfi JD. Encephale; 1991 Oct; 17(4):295-300. PubMed ID: 1959498 [Abstract] [Full Text] [Related]
10. Ipsapirone: evidence for efficacy in depression. Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM. Psychopharmacol Bull; 1990 Jun; 26(2):219-22. PubMed ID: 1978372 [Abstract] [Full Text] [Related]
11. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522 [Abstract] [Full Text] [Related]
12. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Borison RL, Albrecht JW, Diamond BI. Psychopharmacol Bull; 1990 Apr; 26(2):207-10. PubMed ID: 1978371 [Abstract] [Full Text] [Related]
13. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG. J Clin Psychiatry; 1997 Apr; 58 Suppl 11():19-23. PubMed ID: 9363044 [Abstract] [Full Text] [Related]
14. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. Cohn JB, Wilcox CS. J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128 [Abstract] [Full Text] [Related]
15. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, García-Valencia CE, Tortoriello J. Planta Med; 2007 Jul; 73(8):713-7. PubMed ID: 17562493 [Abstract] [Full Text] [Related]
16. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Ballenger JC, McDonald S, Noyes R, Rickels K, Sussman N, Woods S, Patin J, Singer J. Psychopharmacol Bull; 1991 Jul; 27(2):171-9. PubMed ID: 1681563 [Abstract] [Full Text] [Related]
17. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Fresquet A, Sust M, Lloret A, Murphy MF, Carter FJ, Campbell GM, Marion-Landais G. Ann Pharmacother; 2000 Feb; 34(2):147-53. PubMed ID: 10676820 [Abstract] [Full Text] [Related]
18. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety. Small GW, Bystritsky A. J Clin Psychiatry; 1997 Feb; 58 Suppl 11():24-9. PubMed ID: 9363045 [Abstract] [Full Text] [Related]
19. The effect of lorazepam on hypertension-associated anxiety: a double-blind study. Hart WL, Parmley LF. J Clin Psychiatry; 1978 Oct; 39(10 Pt 2):41-5. PubMed ID: 30767 [Abstract] [Full Text] [Related]
20. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [Abstract] [Full Text] [Related] Page: [Next] [New Search]